Education
About Us
Working with TipRanks
Follow Us
Genetec Corp. (JP:4492)
:4492
Top Page
Genetec Corp.
(4492)
76Outperform
Genetec Corp. (4492) vs. S&P 500 (SPY)
Market Cap
¥6.00B
Dividend Yield3.46%
Average Volume (3M)19.84K
Price to Earnings (P/E)13.9
Beta (1Y)1.31
Revenue Growth16.57%
EPS Growth5.53%
CountryJP
Employees347
SectorTechnology
Sector Strength67
IndustrySoftware - Application
Share Statistics
EPS (TTM)37.48
Shares Outstanding11,687,000
10 Day Avg. Volume16,000
30 Day Avg. Volume19,843
Financial Highlights & Ratios
PEG Ratio2.51
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Genetec Corp. Business Overview & Revenue Model
Company DescriptionGenetec Corp. (4492) is a leading biotechnology company that specializes in the development and commercialization of innovative genetic solutions. The company operates in the biotechnology sector, focusing on the research and development of genetic engineering technologies, including gene editing, gene therapy, and synthetic biology. Genetec Corp. aims to address critical healthcare challenges by providing advanced genetic technologies and services to improve human health and well-being.
How the Company Makes MoneyGenetec Corp. generates revenue primarily through the commercialization of its proprietary genetic technologies and solutions. The company earns money by licensing its technologies to pharmaceutical and biotechnology companies, allowing them to incorporate these innovations into their own product pipelines. Additionally, Genetec Corp. engages in strategic partnerships and collaborations with research institutions and healthcare organizations to co-develop new therapies and treatments, sharing the resulting revenues. The company may also receive funding through grants and government contracts aimed at advancing genetic research and application. Its earnings are further supplemented by offering consulting services and selling genetic testing kits directly to consumers or healthcare providers.
Genetec Corp. Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | ||||
| Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 7.15B | 5.86B | 4.68B | 4.08B | 4.72B | Gross Profit |
| 2.91B | 2.32B | 1.96B | 1.56B | 1.61B | EBIT |
| 629.43M | 105.88M | 190.09M | 254.16M | 336.00M | EBITDA |
| 783.24M | 245.09M | 153.83M | 301.93M | 356.00M | Net Income Common Stockholders |
| 414.77M | 23.76M | 56.64M | 173.41M | 212.00M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 1.17B | 1.08B | 1.04B | 1.48B | 1.12B | Total Assets |
| 4.52B | 4.12B | 3.25B | 2.84B | 2.69B | Total Debt |
| 640.00M | 976.09M | 50.62M | 75.00M | 165.00M | Net Debt |
| -528.08M | -99.69M | -994.23M | -1.41B | -958.00M | Total Liabilities |
| 2.31B | 2.26B | 1.39B | 1.02B | 1.05B | Stockholders Equity |
| 2.21B | 1.87B | 1.86B | 1.83B | 1.64B |
| Cash Flow | Free Cash Flow | |||
| 495.19M | -359.44M | -176.37M | 406.28M | 51.90M | Operating Cash Flow |
| 602.37M | -223.12M | -24.03M | 443.26M | 61.30M | Investing Cash Flow |
| -55.73M | -439.20M | -98.15M | -38.53M | -49.39M | Financing Cash Flow |
| -410.02M | 714.93M | -94.71M | -76.04M | 403.57M |
Genetec Corp. Technical Analysis
Positive
520.00
Price Trends
503.78
Positive
527.62
Negative
567.73
Negative
Market Momentum
4.44
Negative
53.32
Neutral
50.31
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4492, the sentiment is Positive. The current price of 520 is above the 20-day moving average (MA) of 501.10, above the 50-day MA of 503.78, and below the 200-day MA of 567.73, indicating a neutral trend. The MACD of 4.44 indicates Negative momentum. The RSI at 53.32 is Neutral, neither overbought nor oversold. The STOCH value of 50.31 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4492.
Genetec Corp. Peers Comparison
Overall Rating
UnderperformOutperform
Sector (60)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | $4.75T | 26.58 | 8.97% | 0.76% | -1.55% | 17.24% | |
76 Outperform | ¥6.00B | 13.88 | 3.46% | 16.57% | 5.53% | ||
75 Outperform | $81.84B | 3.20 | 21.05% | 2.93% | 10.79% | 138.11% | |
73 Outperform | $5.80T | 26.08 | 11.70% | 0.85% | -5.48% | -11.96% | |
73 Outperform | $289.47B | 7.59 | 9.28% | 4.07% | 2.73% | ― | |
70 Outperform | $3.94T | 11.82 | 7.23% | 2.32% | 1.72% | -33.60% | |
60 Neutral | $10.78B | 10.47 | -6.71% | 2.99% | 7.58% | -12.08% |
* Technology Sector Average
Performance Comparison
JP:4492
Genetec Corp.
520.00
-384.33
-42.50%
JP:6752
Panasonic
1,682.00
348.96
26.18%
JP:6703
OKI Electric Industry Company
945.00
-215.40
-18.56%
JP:6701
NEC
3,599.00
1,444.32
67.03%
JP:6702
Fujitsu
3,215.00
906.60
39.27%
JP:6770
Alps Alpine Co
1,354.50
-117.55
-7.99%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.